Medical management of patients with aneurysmal subarachnoid haemorrhage

International Journal of Stroke

Volumn 3, Issue 3, 2008, Pages 193-204

  Rinkel, Gabriel J E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Aneurysm; Nimodipine; Subarachnoid haemorrhage; Vasospasm; Volume therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFIBRINOLYTIC AGENT; CALCIUM ANTAGONIST; CODEINE; CORTICOSTEROID; DIPYRIDAMOLE; ENOXAPARIN; ESMOLOL; FIBRINOLYTIC AGENT; FLUDROCORTISONE ACETATE; HEPARIN; HEPARINOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; NIMODIPINE; PARACETAMOL; PIRITRAMIDE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRAMADOL; TRANEXAMIC ACID; UNINDEXED DRUG;

BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; COMPRESSION GARMENT; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; FEVER; FLUID INTAKE; HEADACHE; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LOW DRUG DOSE; LUNG EDEMA; LUNG EMBOLISM; NATRIURESIS; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEIZURE; SUBARACHNOID HEMORRHAGE; VENOUS THROMBOEMBOLISM;

BLOOD PRESSURE; BODY FLUIDS; ELECTROLYTES; GLASGOW COMA SCALE; HUMANS; INTRACRANIAL ANEURYSM; MONITORING, PHYSIOLOGIC; SUBARACHNOID HEMORRHAGE;

EID: 48749124633     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2008.00210.x     Document Type: Review

References (103)

1. Hop JW, Rinkel GJE, Algra A, van Gijn J: Case-fatality rates and functional outcome after subarachnoid hemorrhage: A systematic review. Stroke 1997; 28: 660-4.
2. Huang J, Van Gelder JM: The probability of sudden death from rupture of intracranial aneurysms: A meta-analysis. Neurosurgery 2002; 51: 1101-7.
3. Hackett ML, Anderson CS, ACROSS study. Health outcomes 1 year after subarachnoid hemorrhage. An international population-based study. Neurology 2000; 55: 658-62.
4. van der Schaaf IC, Algra A, Wermer MJ et al. Endovascular coiling versus neurosurgical clipping for patients with aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005; 19 CD003085.
5. Fergusen S, Macdonald RL: Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007; 60: 658-67.
6. Gruber A, Reinprecht A, Bavinzski G, Czech T, Richling B: Chronic shunt-dependent hydropcephalus after early surgical and early endovascular treatment of ruptured intracranial aneurysms. Neurosurgery 1999; 44: 503-12.
7. Macrea LM, Tramer MR, Walder B: Spontaneous subarachnoid hemorrhage and serious cardiopulmonary dysfunction - a systematic review. Resuscitation 2005; 65: 139-48.
8. Wartenberg KE, Schmidt JM, Claassen J et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med 2006; 34: 617-23.
9. Brilstra EH, Rinkel GJE, Algra A, van Gijn J: Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. Neurology 2000; 55: 1656-60.
10. Van Rooij WJ, Sluzewski M, Beute GN, Nijssen PC: Procedural complications of coiling of ruptured intracranial aneurysms: Incidence and risk factors in a consecutive series of 681 patients. AJNR Am J Neuroradiol 2006; 27: 1498-501.
11. Bardach NS, Zhao S, Gress DR, Lawton MT, Johnston SC: Association between subarachnoid hemorrhage outcomes and number of cases treated at California hospitals. Stroke 2002; 33: 1851-6.
12. Sasaki T, Sato M, Oinuma M et al. Management of poor-grade patients with aneurysmal subarachnoid hemorrhage in the acute stage: Importance of close monitoring for neurological grade changes. Surg Neurol 2004; 62: 531-5.
13. Grote E, Hassler W: The critical first minutes after subarachnoid hemorrhage. Neurosurg 1988; 22: 654-61.
14. Sarker SJ, Heuschmann PU, Burger I et al. Predictors of survival after haemorrhagic stroke in a multi-ethnic population: The South London Stroke Register (SLSR). J Neurol Neurosurg Psychiatry 2008; 79: 260-5.
15. Koffijberg H, Buskens E, Granath F et al. Subarachnoid haemorrhage in Sweden 1987-2002: Regional incidence and case fatality rates. J Neurol Neurosurg Psychiatry 2008; 29: 294-9.
16. Wijdicks EFM, Vermeulen M, Murray GD, Hijdra A, van Gijn J: The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92: 111-7.
17. Hasan D, Vermeulen M, Wijdicks EFM, Hijdra A, van Gijn J: Effect of fluid intake and antihypertensive treatment on cerebral ischemia after subarachnoid hemorrhage. Stroke 1989; 20: 1511-5.
18. Varon J, MaTik PE: Clinical review: the management of hypertensive crises. Crit Care 2003; 7: 374-84.
19. Wijdicks EFM, Vermeulen M, Hijdra A, van Gijn J: Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: Is fluid restriction harmful? Ann Neurol 1985; 17: 137-40.
20. Wijdicks EFM, Vermeulen M, ten Haaf JA, Hijdra A, Bakker WH, van Gijn J: Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm. Ann Neurol 1985; 18: 211-6.
21. Oliveira-Filho J, Ezzeddine MA, Segal AZ et al. Fever in subarachnoid hemorrhage. Relationship to vasospasm and outcome. Neurology 2001; 56: 1299-304.
22. Rinkel GJE, Feigin VL, Algra A, van Gijn J: Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004; 4 CD000483.
23. Qureshi AI, Suri MF, Sung GY et al. Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 50: 749-55.
24. Harrigan MR: Cerebral salt wasting syndrome. Crit Care Clin 2001; 17: 125-38.
25. Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL: Central pontine myelinolysis, an update. Neurol Res 2006; 28: 360-6.
26. Martin RJ: Central pontine and extrapontiTe myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl. 3): Iii22-8.
27. Suarez JI, Qureshi AI, Parekh PD et al. Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg Anesthesiol 1999; 11: 178-84.
28. Wijdicks EF, Vermeulen M, van Brummelen P, van Gijn J: The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1988; 90: 209-14.
29. Hasan D, Lindsay KW, Wijdicks EF et al. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989; 20: 1156-61.
30. Mori T, Katayama Y, Hirayama T: Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1999; 91: 947-52.
31. Katayama Y, Haraoka J, Hirabayashi H et al. A randomized controlled trial of hydrocortisone against Hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007; 38: 2373-5.
32. Feigin VL, Anderson N, Rinkel GJE, Algra A, van Gijn J, Bennett DA: Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev 2005; (3): CD004583.
33. Dorhout Mees SM, van Dijk GW, Algra A, Kempink DR, Rinkel GJE: Glucose levels and outcome after subarachnoid hemorrhage. Neurology 2003; 61: 1132-3.
34. Frontera JA, Fernandez A, Claassen J et al. Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. Stroke 2006; 37: 199-203.
35. Bilotta F, Spinelli A, Giovannini F, Doronzio A, Delfini R, Rosa G: The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in Neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: A randomized prospective pilot trial. J Neurosurg Anesthesiol 2007; 19: 156-60.
36. Takagi K, Tsuchiya Y, Okinaga K, Hirata M, Nakagomi T, Tamura A: Natural hypothermia immediately after transient global cerebral ischemia induced by spontaneous subarachnoid hemorrhage. J Neurosurg 2003; 98: 50-6.
37. Rousseaux P, Scherpereel B, Bernard MH, Graftieaux JP, Guyot JF: Fever and cerebrovasospasm in ruptured intracranial aneurysms. Surg Neurol 1980; 14: 459-65.
38. Fernandez A, Schmidt JM, Claassen J et al. Fever after subarachnoid hemorrhage. Risk factors and impact on outcome. Neurology 2007; 68: 1013-9.
39. Vermeulen M, Lindsay KW, Murray GD et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311: 432-7.
40. Siironen J, Juvela S, Varis J et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003; 99: 953-9.
41. Amaragiri SV, Lees TA: Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; (3): CD001484.
42. Black PM, Crowell RM, Abbott WM: External pneumatic calf compression reduces deep venous thrombosis in patients with ruptured intracranial aneurysms. Neurosurgery 1986; 18: 25-8.
43. Lacut K, Bressollette L, Le Gal G et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 2005; 65: 865-9.
44. Butzkueven H, Evans AH, Pitman A et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology 2000; 55: 1315-20.
45. Lin CL, Dumont AS, Lieu AS et al. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg 2003; 99: 978-85.
46. Pinto AN, Canhao P, Ferro JM: Seizures at the onset of subarachnoid haemorrhage. J Neurol 1996; 243: 161-4.
47. Claassen J, Bateman BT, Willey JZ et al. Generalized convulsive status epilepticus after nontraumatic subarachnoid hemorrhage: The nationwide inpatient sample. Neurosurgery 2007; 61: 60-5.
48. Dennis LJ, Claassen J, Hirsch LJ, Emerson RG, Connolly ES, Mayer SA: Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery 2002; 51: 1136-44.
49. Claassen J, Hirsch LJ, Frontera JA et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care 2006; 4: 103-12.
50. Kull LL, Emerson RG: Continuous EEG monitoring in the intensive care unit: Technical and staffing considerations. J Clin Neurophysiol 2005; 22: 107-18.
51. Molyneux AJ, Kerr RS, Yu LM et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005; 366: 809-17.
52. Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MD: Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry 1992; 55: 753-7.
53. Rosengart AJ, Huo JD, Tolentino J et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007; 107: 253-60.
54. McLaughlin N, Bojanowski MW, Girard F, Denault A: Pulmonary edema and cardiac dysfunction following subarachnoid hemorrhage. Can J Neurol Sci 2005; 32: 178-85.
55. Parr MJ, Finfer SR, Morgan MK: Reversible cardiogenic shock complicating subarachnoid haemorrhage. BMJ 1996; 313: 681-3.
56. Schuiling WJ, Dennesen PJ, Rinkel GJE: Extracerebral organ dysfunction in the acute stage after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2005; 3: 1-10.
57. Deehan SC, Grant IS: Haemodynamic changes in neurogenic pulmonary oedema: Effect of dobutamine. Intensive Care Med 1996; 22: 672-6.
58. Kahn JM, Caldwell EC, Deem S, Newell DW, Heckbert SR, Rubenfeld GD: Acute lung injury in patients with subarachnoid hemorrhage: Incidence, risk factors, and outcome. Crit Care Med 2006; 34: 196-202.
59. Muench E, Bauhuf C, Roth H et al. Effects of positive end-expiratory pressure on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation. Crit Care Med 2005; 33: 2367-72.
60. Brilstra EH, Algra A, Rinkel GJE, Tulleken CAF, van Gijn J: Effectiveness of neurosurgical clip application in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 97: 1036-41.
61. Ohkuma H, Tsurutani H, Suzuki S: Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 2001; 32: 1176-80.
62. Roos YBWEM, Rinkel GJE, Vermeulen M, Algra A, van Gijn J: Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; (2): CD001245.
63. Roos YBWEM, STAR Study Group: Antifibrinolytic treatment in subarachnoid hemorrhage. A randomized placebo-crontrolled trial. Neurology 2000; 54: 77-82.
64. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE: Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002; 97: 771-8.
65. Pickard JD, Kirkpatrick PJ, Melsen T et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S117-20.
66. Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF: Patterns of Cerebral Infarction in aneurysmal subarachnoid hemorrhage. Stroke 2005; 36: 992-7.
67. Rabinstein AA, Friedman JA, Weigand SD et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 1862-6.
68. Dorhout Mees SM, Rinkel GJE, Feigin V et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; (3): CD000277.
69. Pickard JD, Murray GD, Illingworth R et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298: 636-42.
70. Barth M, Capelle HH, Weidauer S et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage. A prospective, randomized, double-blind phase IIa study. Stroke 2007; 38: 330-6.
71. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T: Application of nicardipine prolonged-release implants: Analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 2005; 56: 895-902.
72. van den Bergh WM, Algra A, Berkelbach van der Sprenkel JW, Tulleken CAF, Rinkel GJE: Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003; 52: 276-82.
73. Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ: Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: A randomized study. Neurosurgery 2006; 58: 1054-65.
74. Juvela S, Kaste M, Hillbom M: Platelet thromboxane release after subarachnoid hemorrhage and surgery. Stroke 1990; 21: 566-71.
75. Ohkuma H, Suzuki S, Kimura M, Sobata E: Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1991; 22: 854-9.
76. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJE: Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; (4): CD006184.
77. Lynch JR, Wang H, McGirt MJ et al. Simvastatin Reduces Vasospasm After Aneurysmal Subarachnoid Hemorrhage. Results of a pilot randomized clinical trial. Stroke 2005; 36: 2024-6.
78. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005; 36: 1627-32.
79. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 2007; 38: 1545-50.
80. Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves WM: Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia and New Zealand. J Neurosurg 1996; 84: 221-8.
81. Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM: A randomized, double blind, vehicle controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid haemorrhage: A cooperative study in North America. J Neurosurg 1997; 86: 467-74.
82. Lanzino G, Kassell NF: Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999; 90: 1018-24.
83. Lanzino G, Kassell NF, Dorsch NW et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999; 90: 1011-7.
84. Asano T, Takakura K, Sano K et al. Effects of a hydroxyl radical scavanger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: Results of a multicenter, placebo-controlled double-blind trial. J Neurosurg 1996; 84: 792-803.
85. Saito I, Asano T, Sano K et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998; 42: 269-77.
86. Saito I, Asano T, Ochiai C, Takakura K, Tamura A, Sano K: A double-blind clinical evaluation of the effect of Nizofenone (Y-9179) on delayed ischemic neurological deficits following aneurysmal rupture. Neurol Res 1983; 5: 29-47.
87. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM: Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000; 93: 992-7.
88. Vajkoczy P, Meyer B, Weidauer S et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103: 9-17.
89. Nogueira RG, Bodock MJ, Koroshetz WJ et al. High-dose Bosentan in the Prevention and Treatment of Subarachnoid Hemorrhage-induced Cerebral Vasospasm: An open-label feasibility study. Neurocrit Care 2007; 7: 194-202.
90. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV: Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: A double blind randomised clinical trial. Acta Neurochir (Wien) 2007; 49: 1089-101.
91. Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH: Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 2004; 100: 215-24.
92. Amin-Hanjani S, Ogilvy CS, Barker FG: Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurg 2004; 54: 326-34.
93. Hamada JI, Kai Y, Morioka M et al. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the Cisterna Magna. A prospective randomized study. Stroke 2003; 34: 2549-54.
94. Kosnik EJ, Hunt WE: Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg 1976; 45: 148-54.
95. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP: Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982; 11: 337-43.
96. Amin-Hanjani S, Schwartz RB, Sathi S, Stieg PE: Hypertensive encephalopathy as a complication of hyperdynamic therapy for vasospasm: report of two cases. Neurosurgery 1999; 44: 1113-6.
97. Wartenberg KE, Parra A: CT and CT-perfusion findings of reversible Leukoencephalopathy during triple-H therapy for symptomatic subarachnoid hemorrhage-related vasospasm. J Neuroimaging 2006; 16: 170-5.
98. Hoh BL, Ogilvy CS: Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am 2005; 16: 501-16.
99. Rabinstein AA, Friedman JA, Nichols DA et al. Predictors of outcome after endovascular treatment of cerebral vasospasm. AJNR Am J Neuroradiol 2004; 25: 1778-82.
100. Fandino J, Kaku Y, Schuknecht B, Valavanis A, Yonekawa Y: Improvement of cerebral oxygenation patterns and metabolic validation of superselective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. J Neurosurg 1998; 89: 93-100.
101. Polin RS, Hansen CA, German P, Chadduck JB, Kassell NF: Intra-arterially administered papaverine for treatment of symptomatic cerebral vasospasm. Neurosurg 1998; 42: 1256-64.
102. Smith WS, Dowd CF, Johnston SC et al. Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 2518-22.
103. European CGRP in subarachnoid haemorrhage study group Effect of calcitonine-gene-related peptide in patients with delayed postoperative cerebral ischaemia after aneurysmal subarachnoid haemorrhage. Lancet 1992; 339: 831-4.